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Abstract
Realizing the full potential of iron oxide nanoparticles (IONP) for cancer diagnosis and ther-
apy requires selective tumor cell accumulation. Here, we report a systematic analysis of two
key determinants for IONP homing to human breast cancers: (i) particle size and (ii) active
vs passive targeting. In vitro, molecular targeting to the HER2 receptor was the dominant
factor driving cancer cell association. In contrast, size was found to be the key determinant
of tumor accumulation in vivo, where molecular targeting increased tumor tissue concentra-
tions for 30 nm but not 100 nm IONP. Similar to the in vitro results, PEGylation did not influ-
ence in vivo IONP biodistribution. Thus, the results reported here indicate that the in vitro
advantages of molecular targeting may not consistently extend to pre-clinical in vivo set-
tings. These observations may have important implications for the design and clinical trans-
lation of advanced, multifunctional, IONP platforms.
Introduction
Advances in nanotechnology are now driving a revolution in cancer detection and treatment,
and iron oxide nanoparticles (IONPs) were some of the first nanomaterials to see application
in oncology. In the field of bioimaging, IONPs have seen extensive application as contrast
agents for magnetic resonance imaging (MRI) [1–6]. With respect to therapy, studies by
Gilchrist et al. in the mid-20th century suggested that lymphatic metastasis could be therapeuti-
cally heated by activating localized IONPs via an alternating magnetic field [7]. In the decades
following this initial proof of concept study, other groups have successfully implemented this
treatment modality both in vitro [8–16] and in vivo [8–12]. In addition to killing cancer cells
directly, hyperthermia can enhance the efficacy of radiation and chemotherapies[17,18] and
can indirectly stimulate the innate anti-cancer immune response [19,20]. Ultimately, however,
the therapeutic index (defined in humans as the TD50/ED50) of IONP therapies and the
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imaging sensitivity of IONP contrast agents is a function of differential particle concentrations
at sites of malignancy versus healthy tissues.
In the case of nanoparticles that lack targeting moieties, tumor accumulation is dependent
upon direct injection, selective tumor embolization, or passive targeting as a result of uptake
by either the reticuloendothelial system or the enhanced permeability and retention (EPR) ef-
fect [4,17,18,21]. With more advanced platforms, nanoparticles may be actively targeted to
cancer cells by surface functionalization with various moieties. Examples include natural li-
gands for cell surface receptors, small molecules, nucleic acids, carbohydrates, peptides, and
non-immunoglobulin scaffolds [4,21]. To date, however, antibodies have been the most wide-
ly used targeting ligands [22–25]. Monoclonal antibodies (mAb) have shown particular
promise in localizing IONP for in vivomagnetic hyperthermia [26,27]. Of even greater rele-
vance to the current study, Trastuzumab (Tmab; Herceptin) has been used to target IONP to
human breast cancers in vitro and in vivo, although the latter success required direct tumor
injection[28–32]. However, further studies are needed to fully understand key parameters
that control the efficiency with which IONP selectively home to cancer cells following sys-
temic administration in vivo.
While yielding promising preliminary results, mAbs have inherent limitations as nanoparti-
cle targeting agents. With an average molecular weight of 160,000 daltons and diameters of up
to 15 nm, full length IgG antibodies are relatively large molecules that can significantly alter
IONP size and surface properties, thereby diminishing selective tumor localization and
diagnostic/therapeutic utility[4]. Additionally, the Fc portion of full length antibodies has the
potential to compromise tumor specificity due to off-target binding by various Fc receptors ex-
pressed in healthy tissues [33,34]. Smaller, engineered antibody fragments directly address
some of these inherent limitations. To better capitalize on active IONP targeting for human
breast cancer, the studies described here employed a monovalent Fab’ fragment of Tmab (re-
ferred to hereafter as Tfab). A systematic approach was applied to nanoparticle design, functio-
nalization, in vitro characterization, and analysis of in vivo biodistribution. This controlled,
comparative study yields new insights into the relationships between IONP size, molecular tar-
geting, surface functionalization, and accumulation on human breast cancer cells.
Methods
For cell line information, see S1 File.
Tfab conjugation to 30 nm and 100 nm iron Oxide Nanoparticles (IONPs)
Trastuzufab (Tfab) protein sequence was reformatted from its corresponding and commercial
full IgG molecule, Trastuzumab (trade name, Herceptin) (Tmab) protein sequence available
from literature. CMVR VRC01 expression vectors (NIH AIDS reagent program, Germantown,
MD) separately harboring Tfab light chain and heavy chain were co-transfected into suspen-
sion HEK 293 cells and purified using Kappa select and superdex 75 chromatography columns
(GE Healthcare, Pittsburgh, PA). Reductive activation and chemical conjugation of purified
Tfab were performed as described in supplemental methods (S1 File).
30 nm and 100 nm aminodextran coated IONPs were purchased from BioPal (Worcester,
MA) and Micromo Partikeltechnologie GmbH (Germany), respectively. To perform site conju-
gation, Sulfo GMBS (Thermo Scientific, Rockford, IL) was added to IONPs and incubated at
room temperature for 2 hours. Cysteine reduced Tfab was added to the activated IONP at an
equal w/w ratio and incubated at room temperature for 16 hours at 4°C. All process was per-
formed in a sterile environment using sterile and endotoxin free buffers. For PEGylation, PEG
thiol (Laysan Bio, AL) average molecular weight was reduced with TCEP and assayed by the
Tumor Cells and Iron Oxide Nanoparticles Targeting
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barium chloride/iodine method[35]. Mixed PEGylated Tfab and IONPs were prepared as de-
scribed for non-PEGylated IONPs (see supporting information for details).
30 nm and 100 nm Tfab functionalized Nanoparticles binding studies
Quantification of the number of Tfab/IONPs was performed as described in supplemental
methods (S1 File). The rHER2-his (AcroBiosystems, Bethesda, MD) and cells (SKBR3 and BT-
474) binding studies procedures of 30 nm and 100nm Tfab functionalized nanoparticles are de-
scribed in details in supplemental methods (S1 File).
BT-474 tumor model
All mice were cared for according to approved Dartmouth College Institutional Animal Care
and Use Committee (IACUC) animal protocol (protocol number hoop.pj.8). This study was
approved by the Dartmouth College IACUC. All efforts were made to minimize animals suffer-
ing. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were obtained from Jackson Laboratories
or an in-house stock originally from Jackson Laboratories. At 8–11 weeks old, mice were im-
planted below the mammary fat pad with 5 million BT-474 cells in 100 μl of a three part mix-
ture of rat tail collagen I (BD Biosciences, San Jose, CA), MatrigelTM basement membrane
matrix (BD Biosciences, San Jose, CA) and serum-free DMEM-F12 50/50 using a 1ml syringe
and a 30G needle. Mice were put on study upon reaching a tumor volume of 100–200mm3, as
measured by calipers and calculated using an ellipsoid approximation.
30 nm and 100 nm Tfab functionalized Nanoparticles administration
IONP dose was calculated using mouse body mass (g). Doses of 0.08 mg Fe/g mouse were used
and IONPs-Tfab stocks were diluted with PBS to the target concentration immediately prior to
injection. A 1ml syringe with 30g needle was primed and loaded with the full injection dose,
and half the volume marked off. Mice were anesthetized using isoflurane and secured on a
heated, vented surface with an isoflurane nose cone for injection. Half the IONP dose or an
equivalent volume of PBS was injected intravenously into the tail vein; the mouse was then al-
lowed to wake up on the heated surface, and was then returned to her cage. Two hours follow-
ing the first injection, the syringe was drawn back to recover any void volume in the needle and
the needle was replaced with a fresh tip. The mouse was then re-anesthetized and injected with
the second half of the IONP dose. 24 hours after IONPs injection, mice were euthanized ac-
cording to approved protocol with an overdose of isoflurane and checked for pain stimulus re-
sponse. Tissues harvesting and ICP-MS digestion were performed as described in
supplemental methods (S1 File).
Results
Design, Production, and Analysis of Tfab
To minimize the molecular targeting moiety’s contribution to overall IONP size, an antigen
binding fragment (Fab’) of the FDA approved monoclonal antibody Tmab was engineered as
described in the methods section. The workflow for functionalization and conjugations of the
engineered antibody and IONPs is shown in Fig. 1A. This antibody fragment, Tfab, was con-
structed such that the heavy chain’s C-terminal cysteine (residue 229) was left unpaired
(S1B Fig.). This design ultimately enabled site specific conjugation of the Tfab to maleimide-
PEG2-Biotin, fluorescein-5-maleimide or maleimide-IONPs. The desired monomeric Tfab
fraction was isolated by Kappa Select affinity purification and size exclusion chromatography
of recombinant Tfab expressed in HEK 293 cells (Fig. 1B).
Tumor Cells and Iron Oxide Nanoparticles Targeting
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Fig 1. Purification and characterization of Tfab antibody fragment. (A) Schematic illustration of workflow
for Tfab and IONP functionalization. Monomeric Tfab is subjected to reduction/activation using 20 mM
cysteine followed by conjugation with Maleimiede-PEG2-Biotin, Fluorescein-5-Maleimide, or Maleimide-
IONP. (B) Size exclusion purification chromatogram. The blue curve represents UV absorbance at 280 nm
and dashes lines represent the collected monomeric Tfab fraction.
doi:10.1371/journal.pone.0115636.g001
Tumor Cells and Iron Oxide Nanoparticles Targeting
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Tfab specifically binds to recombinant HER2 and HER2 expressing
tumor cells
To enable functional analysis of the purified Tfab, the free cysteine of the heavy chain was capped
with a hetero bifunctional maleimide-PEG2-biotin of 526 Da. Upon reaction with the biotin moi-
ety, mass spectral analysis showed the Tfab base peak shifted from 47984 Da to 48510 Da, consis-
tent with the addition of a single maleimide-PEG2-biotin molecule (S1F Fig.). Binding of
maleimide-PEG2-biotin labeled Tfab to recombinant HER2 (rHER2) was initially analyzed by
ELISA. As a performance benchmark, analogous studies were conducted with commercially
sourced Tmab IgG (Herceptin). The engineered Tfab fragment and the full length IgG antibody
(Tmab) exhibited equivalent sub-nanomolar EC50 values (Table 1 and S2A Fig.). Additionally,
serial dilutions of the Tfab-Maleimide-PEG2-biotin were employed in rHER2 competition bind-
ing experiments against a single saturating concentration of Tmab IgG (Table 1 and S2B Fig.).
The engineered Tfab displaced Tmab binding with low nanomolar IC50, indicating that it re-
tained the same epitope specificity as the full length parental IgG. Subsequently, more detailed
rHER2 binding kinetics were analyzed using biolayer interferometry (Table 1 and S3 Fig.). Tfab-
maleimide-PEG2-biotin and Tmab were immobilized on streptavidin and rprotein A biosensors
tips, respectively, and then assayed with rHER2-his protein. While the on rates of both antibodies
were similar, Tfab exhibited a 10-fold slower apparent off rate compared to the parental IgG. As
a result, the engineered Tfab possessed a marginally improved apparent equilibrium dissociation
constant relative to full length Tmab (KD = 0.19 nM versus 1.0 nM, respectively). It is likely that
this small difference resulted from the high affinity biotin-streptavidin capture interaction for
Tfab versus the lower Protein A-Fc capture interaction for Tmab IgG. Importantly, no binding
of Tfab-maleiemide-PEG2-biotin or Tmab was observed when rHER3 protein was used as ana-
lyte in either ELISA or bio-layer interferometry experiments (S2 and S3 Figs.). In aggregate, the
quantitative binding studies with rHER2 demonstrated that the engineered Tfab has the same
epitope specificity and monovalent binding affinity as its full length IgG counterpart.
While the above in vitro studies demonstrated that Tfab-maleimide-PEG2-biotin efficiently
bound both immobilized and soluble rHER2, the ultimate in vivo utility of targeted IONP is de-
pendent upon antibody recognition of the HER2 receptor in its biological context. To assess
cellular binding, the free heavy chain cysteine of purified and activated Tfab was capped with
fluorescein-5-Maleimide, and the fluorescent conjugate (Tfab-fluorescein-5-Maleimide) was
assayed by flow cytometry with a panel of live human cancer cells exhibiting either high or low
HER2 expression levels (S4 Fig.). After one hour incubation, Tfab-fluorescein-5-Maleimide
was found to exhibit low nanomolar binding affinity for both BT-474 and SKBR3 breast cancer
lines (Table 2 and S2C Fig.), each of which expresses high levels of HER2. In contrast, no Tfab-
fluorescein-5-Maleimide binding was detected on live MCF7 (S2C Fig.), a breast cancer cell
Table 1. In vitro binding affinity of Tfab and Tmab.
Tfab Tmab
EC50 rHER2 (nM) 0.1 0.1
IC50 rHER2* (nM) 12 N/A
kon (M
-1s-1) 1.42E+05 ± 500 3.03E+05 ± 1000
koff (s
-1) 2.64E-05 ± 2E-06 3.03E-04 ± 2. E-06
KD (nM) 0.19 ± 0.01 1.00 ± 0.01
*IC50 values reflect concentration of Tfab required to compete 50% of saturating Tmab IgG.
Errors are standard deviations from technical triplicates.
doi:10.1371/journal.pone.0115636.t001
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line that expresses lower levels of HER2. Likewise, no binding was observed with live ovarian
cancer cell lines SKOV3 or A2780, both of which were found to express negligible levels of
HER2. Furthermore, serial dilutions of Tfab-maleimide-PEG2-biotin were employed in cellular
competition binding studies (using BT-474 and SKBR3) against a single saturating concentra-
tion of Tmab. Similar to the in vitro competition ELISA studies, the observed low nanomolar
IC50 values demonstrated that the engineered antibody fragment bound the same cellular epi-
tope as the full length IgG (Table 2 and S2D Fig.). As a whole, these data demonstrated that
Tfab efficiently and specifically targeted cancer cells in a HER2-dependent fashion.
Construction and analysis of Tfab functionalized IONP
Having validated Tfab specificity and high affinity for the HER2 receptor, the antibody frag-
ment was conjugated to both small and large maleimide-IONP. These conjugations yielded
matched IONP-Tfab constructs that differed only in their approximate size (~30 nm versus
~100 nm diameter, respectively) and number of Tfab targeting moieties (~10 versus ~90, re-
spectively; Table 3). There was no significant difference in the zeta potential of the targeted and
non-targeted IONP-Tfab constructs, with each showing a near neutral value. HER2 binding of
the 30 nm and 100 nm IONP-Tfab conjugates was evaluated using both recombinant protein
Table 2. Tfab binding performance with breast cancer cell lines.
Cell line EC50 (nM) IC50 (nM)*
SKBR3 4 12
BT-474 3 13
*IC50 values reflect concentration of Tfab required to compete off 50% of a saturating Tmab IgG.
doi:10.1371/journal.pone.0115636.t002
Table 3. Biophysical and biochemical characterization of IONP constructs.
Particle Design Hydrodynamic diameter (nm)a PDIb Zeta Potential (mV) Mean Fab/IONP Mean PEG/IONP
30 nm 24.6 0.152 -0.637 N/A N/A
IONP-Mal
30 nm 26.7 0.128 -1.82 N/A 25
IONP-PEG-Mal
30 nm 30.5 0.148 0.262 10 N/A
IONP-Tfab
30 nm 35.56 0.184 -0.318 10 25
IONP-PEG-Tfab
100 nm 86.88 0.156 -0.978 N/A N/A
IONP-Mal
100 nm 92.6 0.185 0.252 N/A 350
IONP-PEG-Mal
100 nm 95.48 0.177 -1.032 90 N/A
IONP-Tfab
100 nm 102.64 0.224 -0.637 99 350
IONP-PEG-Tfab
a For convenience, the results and discussion sections refer to only two broad categories of particle sizes: larger “100 nm” particles and smaller “30 nm”
particles. The actual diameters of the particles are as shown in this table. Hydrodynamic diameters were measured by dynamic light scattering.
b polydispersity index
doi:10.1371/journal.pone.0115636.t003
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and live cancer cells. ELISAs with rHER2 protein yielded similar sub-nanomolar EC50 values
for both 30 nm and 100 nm IONP-Tfab, whereas no binding was observed with the non-
targeted 30 nm or 100 nm maleimide-IONPs (IONP-Mal) (Fig. 2A and B). These results dem-
onstrated that Tfab binding affinity was not compromised during IONP conjugation, and that
non-targeted IONP-Mal controls had no inherent affinity for the rHER2 receptor. In a similar
fashion, both sizes of IONP-Tfab efficiently bound SKBR3 and BT-474 breast cancer cells after
8 hours incubation (Fig. 2C, D). The more efficient targeting of BT-474 is consistent with the
marginally higher HER2 expression level of these cells (S4 Fig.). Importantly, Tfab-targeted
particles showed no association with MCF7 breast cancer cells (S5 Fig.), which exhibit marked-
ly lower levels of HER2 expression (S4 Fig.). Likewise, neither 30 nm nor 100 nm non-targeted
IONP-Mal bound to HER2 positive cells (Fig. 2C, D). Thus, in vitro cellular homing of both
smaller and larger diameter IONP was critically dependent on the Tfab targeting moiety as
well as high levels of HER2 expression.
To assess the subcellular localization of 30 nm and 100 nm IONP-Tfab conjugates, replicate
samples from the cellular ELISA studies were harvested and analyzed by transmission electron
microscopy (TEM). The TEMmicrographs showed that both 30 nm and 100 nm IONP-Tfab are
Fig 2. In vitro binding studies of IONP. (A) Dose response rHER2 binding curves for 30 nm IONP-Tfab
(closed circles) and 30 nm IONP-Mal (open squares). (B) Dose response rHER2 binding curves for 100 nm
IONP-Tfab (closed circles) and 100 nm IONP-Mal (open squares). (C) Binding of HER2+ breast cancer cells
for 30 nm IONP-Tfab and 30 nm IONP-Mal, both dosed at 100 μg/ml. (D) Binding of HER2+ breast cancer
cells for 100 nm IONP-Tfab and 100 nm IONP-Mal, both dosed at70 μg/ml. Error bars represent
standard deviation.
doi:10.1371/journal.pone.0115636.g002
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internalized by BT-474 and SKBR3 cell lines. During 8 hour in vitro cellular incubations in com-
plete media, both particle sizes were found to accumulate predominantly within intracellular vesi-
cles, and only a small fraction remained localized on the outside of the cell membrane (Fig. 3).
In vivo tumor targeting of IONP
The enhanced in vitro performance of targeted 30 nm and 100 nm IONP-Tfab conjugates sug-
gested that they might also exhibit enhanced tumor localization in vivo. To test this hypothesis, a
single dose (80 μg Fe/g of body mass) of various IONP constructs was administered I/V via the
tail vein into NSG mice bearing human HER2 positive BT-474 tumors. Twenty-four hours post
injection, tissues were harvested and IONP content was quantified by inductively coupled plasma
mass spectrometry (ICP-MS). Consistent with their lack of homing to tumor cells in vitro, the
Fig 3. TEM imaging of subcellular localization following in vitro binding of IONP-Tfab to HER2+ breast
cancer cells. (A) At 20,000Xmagnification in SKBR3 cells, 30 nm IONP-Tfab localize primary to intracellular
vesicles with a smaller proportion remaining bound to the cell surface (arrows). (B) At 20,000X magnification
in BT-474 cells, 30 nm IONP-Tfab exhibit similar localization. (C) At 10,000Xmagnification in SKBR3 cells,
100 nm IONP-Tfab are mainly found in intracellular vesicles (arrows). (D) At 20,000Xmagnification in BT-474
cells, 100 nm IONP-Tfab exhibit similar localization. Scale bars are 100 nm (A, B, D) and 500 nm (C).
doi:10.1371/journal.pone.0115636.g003
Tumor Cells and Iron Oxide Nanoparticles Targeting
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non-targeted 100 nm IONP-Maleimide failed to show statistically significant tumor accumula-
tion in vivo (Fig. 4A). Tumor accumulation of the 100 nm IONP-Tfab conjugates was similarly
negligible, despite the fact that they had exhibited highly efficient HER2 positive cellular targeting
in vitro and despite the presence of Her 2 overexpression in removed tumors frommice (S8
Fig.). Examination of iron concentration in the blood indicated that both 100 nm IONP-Mal and
IONP-Tfab were eliminated from circulation by the 24 hour time point (compare 100 nm groups
to PBS, Fig. 4B). For both targeted and non-targeted 100 nm IONP, the only tissue exhibiting sig-
nificant iron accumulation was the liver (Fig. 4E), where 70–90% of the injected dose was
Fig 4. In vivo biodistribution of IONP.Nanoparticles (80 μg/g body mass) were systemically administered by tail vein injection in NSGmice bearing BT-474
xenograft tumors. Iron content of various tissue compartments was quantified 24 hours post injection by ICP-MS. (A) Tumor, (B) Blood, (C) Heart, (D) Lung,
(E) Liver, (F) Spleen, (G) Kidney. Statistical significance (P<0.05) was analyzed by one way ANOVAwith a Tukey multiple comparison posttest. Solid
brackets with asterisk indicate groups of mice that were not significantly different from each other but were significantly different from other groups outside the
bracket. Significant differences between individual groups, including exceptions to the solid brackets, are indicated by solid arrows marked with an asterisk.
For the heart, non-significance between individual groups (i.e. exceptions to the solid bracket) is indicated by hatched arrows marked with “ns”. For the heart,
the 100 nmmaleimide IONP group was not significantly different from any other group in the panel. N = 4 to 7 per group. Statistical analyses were completed
using GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA).
doi:10.1371/journal.pone.0115636.g004
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ultimately sequestered (Fig. 5C). Thus, for the 100 nm IONP, the in vitro performance advantage
of antibody targeting did not translate to enhanced tumor accumulation in vivo.
The above results suggested that clearance from the blood might be partially responsible for
the poor in vivo performance of 100 nm IONP-Tfab. In an effort to reduce liver sequestration
and extend circulation times, a PEGylated variant of the 100 nm targeted particles (100 nm
IONP-PEG-Tfab) was constructed by covalent attachment of 2 kDa PEG chains (Table 3). In
vitro assays demonstrated that PEGylation did not alter the rHER2 binding properties of either
the targeted or non-targeted IONP (S6B Fig.). Ultimately, however, PEGylation failed to extend
blood circulation times, reduce liver sequestration, or exert any other notable effect on in vivo
biodistribution of 100 nm IONP (Figs. 4, 5A and 5C).
In contrast to the large particles, systemic administration of smaller non-targeted 30 nm
IONP-Mal yielded statistically significant concentrations of iron in the tumor (Fig. 4A), averag-
ing 120 μg/g tissue (1.6% of the injected dose, Fig. 5B). Importantly, the addition of the Tfab tar-
geting moiety significantly increased tumor accumulation to 230 μg/g (3% of the injected dose,
Fig 5. Percent injected IONP dose recovered during in vivo biodistribution studies. Percentages based
on raw values from Fig. 4. (A) Tumor recovery of 100 nm IONP. Values are not statistically significant relative
to background. (B) Tumor recovery of 30 nm IONP. (C) Recovery of 100 nm IONP from seven different
harvested tissues. Liver = grey; blood = red; tumor = black; kidney = cyan; lung = blue; spleen = green;
heart = purple. Note the discontinuous y-axis. (D) Recovery of 30 nm IONP from seven different harvested
tissues. Mean values from N = 4 to 7 mice per group. Error bars in A and B are standard deviation. Statistical
significance (P<0.05) was analyzed by one way ANOVA with a Dunnett comparison posttest.
doi:10.1371/journal.pone.0115636.g005
Tumor Cells and Iron Oxide Nanoparticles Targeting
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Fig. 4A and 5B). Thus, in contrast to the larger 100 nm IONP, the in vitro performance advan-
tage of antibody targeted 30 nm IONP translated to a 2-fold enhanced tumor accumulation in
vivo. Compared to the 100 nm IONP, both the targeted and non-targeted 30 nm IONP exhibited
significantly elevated blood concentrations at 24 hours (Fig. 4B), and both showed substantially
lower concentrations in the liver (Fig. 4E). As seen with the 100 nm IONP, PEGylation of 30 nm
IONP did not alter binding to rHER2 in vitro (S6A Fig.), but neither did PEGylation influence in
vivo biodistribution of the smaller IONP constructs (Fig. 4). Finally, it is worth noting that TEM
analysis of tumor tissue sections revealed that, as was seen in vitro, 30 nm IONPs were internal-
ized by BT-474 cells in the NSG-BT-474 mouse xenograft model (Fig. 6).
Importantly, to minimize variability associated with the experimental procedures, the circu-
latory systems of mice were not perfused prior to tissue harvesting. As a result, all tissues con-
tained some nominal amount of contaminating blood, and the blood vol% of each tissue
contributed proportionally to the measured iron concentrations. In the case of groups receiving
various 100 nm IONP, the nanoparticle concentration in the blood was negligible at 24 hours
(Fig. 4B), and therefore the blood contribution to tissue iron measurements derived almost ex-
clusively from endogenous hemoglobin. This basal contribution from red blood cells is readily
accounted for by the PBS control group. In contrast, all 30 nm IONP exhibited significantly
longer circulation times, and in each case more than 40% of the initially injected dose remained
in the blood at 24 hours (Fig. 5D). Thus, among mice treated with 30 nm IONP, blood contrib-
uted a substantial amount of iron to the total tissue iron concentration.
While the total tumor concentration of IONP is a key factor for many clinical applications,
a fundamental objective of this study was assessing the specific tumor tissue association of vari-
ous IONP constructs. To do so, the biodistribution data was further analyzed by averaging the
iron concentration in each tissue of a given treatment group and normalizing that averaged
value by the averaged blood iron concentration for the same treatment group (S7 Fig.). While
quantification of total iron concentration in the tumor showed that the 100 nm IONP
Fig 6. TEM imaging of IONP subcellular localization in mouse tumors. Following systemic administration
and homing to BT-474 tumor cells in vivo, 30 nm IONP-Tfab (20,000Xmagnification) (A) and 30 nm IONP-
Maleimide (12,000Xmagnification) (B) internalize and concentrate within intracellular vesicles (arrows).
doi:10.1371/journal.pone.0115636.g006
Tumor Cells and Iron Oxide Nanoparticles Targeting
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constructs exhibited no statistically significant difference relative to the PBS control group
(Fig. 4A), normalizing the tumor iron concentrations of each treatment group with the corre-
sponding blood iron concentrations revealed that there was a general (but not always signifi-
cant) trend towards low-level tumor tissue accumulation among the various 100 nm IONP
groups (S7A Fig.). After normalizing to blood iron concentration, tumor specific accumulation
of non-targeted 30 nm IONP-Mal and IONP-PEG-Mal was largely equivalent to that of the
100 nm IONP groups (all ratios ranged between 1.6 and 2.1, S7A Fig.). Thus, the statistically
significant total tumor iron concentrations of the non-targeted 30 nm IONP-Mal and IONP-
PEG-Mal (Fig. 4A) were derived largely from the blood residing within the tumor as opposed
to the tumor tissue itself. In contrast, following normalization to blood iron concentrations, the
tumor tissue accumulation of the targeted 30 nm IONP-Tfab and IONP-PEG-Tfab were highly
significant relative to the PBS control group (P<0.001, S7A Fig.), and this observation demon-
strates that the antibody directed 30 nm IONP specifically localized to tumor tissue following
systemic administration in the mouse BT-474 xenograft model.
Considering the impact of blood volume corrections for the other tissue compartments, the
various 100 nm IONP constructs showed highly significant and specific liver deposition
(S7B Fig.). In contrast, the smaller 30 nm constructs yielded no tissue specific accumulation in
the liver (S7B Fig.). Another key insight from this analysis was that none of the eight IONP
constructs exhibited tissue specific accumulation with the kidney, spleen, lung, or heart (with
one possible exception: heart deposition of 100 nm IONP-Maleimide). Thus, any IONP de-
tected in these healthy tissues appeared to reside within the organs’ fractional blood volume as
opposed to specific association with the organ tissue itself.
Discussion
The magnetic properties of IONP render them highly attractive nanomaterials for imaging and
hyperthermia of cancer [36]. However, their clinical utility depends on differential particle ac-
cumulation in tumor cells; particles must preferentially partition into tumors versus surround-
ing healthy tissues. The enhanced permeability and retention effect can yield some tumor
accumulation for small particles possessing long circulation half-lives, [37] but such passive
targeting may be inadequate for many applications [17,36]. While numerous other IONP stud-
ies have examined separately the effects of antibody targeting in vitro [29,31,38], antibody tar-
geting in vivo [30–32,38], and IONP size in vivo [39], the results presented here are the first
controlled, systematic, comparative analysis of the in vitro versus in vivo interplay between
IONP size, antibody-mediated molecular targeting, and surface modification with PEG.
The targeted 30 nm and 100 nm IONP-Tfab conjugates were both found to specifically bind
to BT-474 and SKBR3 breast cancer cells in vitro (Fig. 2). However, with both rHER2 and
HER2 postivie cell lines, the total iron accumulation was 2 to 3-fold higher for 100 nm IONP-
Tfab versus the smaller 30 nm counterpart. These results are in line with early reports’ showing
that cellular uptake of nanoparticles is dependent upon size and shape, both of which affect the
membrane-wrapping process [40,41]. Nevertheless, the smaller Tfab antibody fragment em-
ployed here yields cellular selectivity similar to that observed with IONP targeted via the full
length Tmab IgG [29,42]. In addition to the cellular specificity observed here, the Tfab target-
ing moiety was found to drive internalization of both 30 nm and 100 nm IONP by HER2 posi-
tive breast cancer cells. The intracellular localization of IONP-Tfab is consistent with previous
reports that employed the full length Tmab targeting moiety [29,43] as well as more recent
studies employing an anti-EGFR single chain antibody fragment[38]. This important phenom-
enon of cellular internalization could have implications for selective partitioning of IONP into
tumors [28] and internalization might also prove critical to therapeutic applications where
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efficacy is modulated by intracellular localization (e.g. magnetic hyperthermia and/or cytotoxic
drug delivery)[18,44].
While functionalization with Tfab enabled HER2 specific cellular targeting of both IONP
sizes in vitro, nanoparticle hydrodynamic radius was the key determinant of tumor accumula-
tion in vivo. Specifically, the current studies show that 100 nm IONP fail to efficiently access
the BT-474 tumor compartment, and active molecular targeting to tumor cell surface antigens
was unable to overcome the underlying barriers. Accelerated blood clearance with increasing
IONP size is a well-known phenomenon[45], and we speculate that liver sequestration com-
bined with poor extravasation prevented tumor targeting of the larger IONP in the current
studies. Interestingly, prior systematic studies with gold nanoparticles showed that larger nano-
particles (60–100 nm) exhibited greater tumor accumulation than smaller nanoparticles
(20 nm) [46]. However, a direct comparison with our results is confounded by substantial dif-
ferences in various experimental design parameters (nanoparticle type, PEGylation, targeting,
and perhaps most importantly, tumor cell type and mouse xenograft model).
While the larger IONP failed to show any tumor homing in vivo, the smaller 30 nm IONP
exhibited statistically significant tumor concentrations, even without the benefit of the Tfab
targeting moiety. This is in contrast to prior reports of non-functionalized 30 nm IONP[26],
which showed no such specific tumor accumulation. This discrepancy might be explained by
differences in the tumor model and/or differences in the properties of the IONP dextran coat-
ing, which was a carboxy-terminated PEG in the former study and a mixture of amine and mal-
eimide groups in the current study. As reported here, the in vivo tumor homing capacity of
smaller IONP was enhanced by the addition of the Tfab targeting moiety, and the extent of
30 nm IONP-Tfab tumor accumulation (13.6% injected dose/g tumor) was equivalent to previ-
ous reports of systemically administered 30 nm IONP-antibody conjugates (13.7% injected
dose/g tumor) [26,27]. Importantly, in the current study, TEM analysis of excised BT-474 NSG
mouse tumors showed that the 30 nm IONP-Tfab retained their cellular-internalizing proper-
ties following systemic administration. This fact could have profound implications for IONP-
mediated therapy of solid tumors.
In addition to active molecular targeting, IONP surface properties are a known determinant
of in vitro and in vivo performance [47]. For example, particle surface charge has been shown to
strongly influence both liver uptake [48] and internalization by cancer cells [49]. However, in the
current study, all IONP constructs exhibited highly similar zeta potentials (Table 3), and there-
fore the observed performance differences among the various IONP were unrelated to surface
charge. Functionalization with PEG is another well studied means of manipulating nanoparticle
pharmacokinetics [46]. Indeed, PEGylation has recently been shown as an effective strategy for
modifying the biodistribution of IONP[50]. In contrast, the in vitro and in vivo results reported
here indicate that PEGylation has little to no effect on IONP performance. This discrepancy with
the earlier report is likely attributable to differences in the cancer cell model and the size and
number of PEGmolecules coupled to the IONP surface. In particular, the prior report estimates
PEG loading at several hundred molecules per IONP, whereas comparably sized particles from
our study bore a mean of 25 PEGmolecules each (Table 3). We did not examine higher loading
densities, as our Tfab targeting moieties represented a significant steric barrier to conjugation of
additional PEGmolecules. Thus, modulating small diameter IONP pharmacokinetics via PEGy-
lation appears to require high surface densities of the conjugated polymer.
Conclusions
In summary, this systematic study of IONP performance reveals that, in vitro, molecular tar-
geting is the key determinant of cancer-specific cellular accumulation, whereas in our BT-474
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xenograft mouse model IONP size is the fundamental gatekeeper with respect to in vivo tumor
targeting. In vivo, molecular targeting significantly enhances tumor accumulation for small but
not large diameter IONP. Our results suggest that non-targeted 30 nm IONP are efficiently de-
livered to the tumor by blood flow, but inside the tumor these particles exhibit only low level
association with the tumor tissue itself. We hypothesize that the tumor functions as a control
volume in dynamic equilibrium, i.e. blood flow continuously carries the non-targeted 30 nm
IONP into and out of the tumor at equal rates. Thus, the tumor concentration of these small
non-targeted IONP is dictated by their concentration in the blood and the percent blood con-
tent of the tumor itself. In contrast, a fraction of the antibody-targeted 30 nm IONP-Tfab is re-
moved from circulation during passage through the tumor and is no longer subject to washout.
This fraction of nanoparticles, bound specifically to tumor tissue, explains the enhanced in vivo
performance of Tfab targeted IONP relative to the non-targeted counterpart. Given the high
blood concentrations of 30 nm IONP-Tfab and 30 nm IONP-PEG-Tfab at 24 hours, we specu-
late that even greater tumor concentrations could be achieved at later time points. We antici-
pate that these results will prove useful to others seeking to employ systemically administered
IONP for treatment or imaging of breast and other solid tumors.
Supporting information available
Details of cell culture conditions; Tfab purification and purity analysis; antibody competition
assays; antibody affinity measurements; cellular binding studies and HER2 receptor profiling;
IONP constructs and specificity; in vivo biodistribution and immunohistochemistry studies.
Supporting Information
S1 Fig. Characterization of Tfab antibody fragment. ClustalW alignment of Tfab and Tmab
light (A) and heavy (B) chains protein sequences. Cysteines 214 and 223 respectively of Tfab
light and heavy chains involved in normal disulfide bonding between light and heavy chain are
underlined. Free Cysteine 229 of Tfab heavy chain enabling site-specific conjugation to reactive
maleimide groups is also underlined. Identical residues are marked with an asterisks and gaps
with a dash. (C) Coomassie stained SDS-PAGE gel (C) of purified of Tfab showing in lanes 1–2
reduced Tfab after size exclusion chromatography (SEC) and the same material following con-
jugation to maleimide-PEG2-Biotin respectively. Lanes 3–4 are, respectively, non-reduced
Tfab after SEC and the same material following conjugation to maleimide-PEG2-Biotin. (D)
Liquid chromatography mass spectrum (LC-MS) of SEC purified of Tfab in reduced form. (E)
LC-MS of SEC purified Tfab following cysteine activation. (F) LC-MS of maleimide-PEG2-Bio-
tin conjugated Tfab. The mass of 23965 corresponds to free light chain conjugated to one mal-
eimide PEG2-biotin molecule (+526 Da). The mass of 25599 corresponds to free heavy chain
conjugated to two maleimide-PEG2-biotin molecules (+1052 Da). The mass of 48510 corre-
sponds to intact Tfab conjugated to one maleimide-PEG2-biotin molecule (+526 Da).
(TIF)
S2 Fig. Tfab binding affinity and competition against Tmab (Herceptin). (A) Representative
ELISA binding profiles of Tfab (red) and Tmab (blue) with rHer2 protein. (B) Competition
ELISA shows Tfab competes with commercial Tmab for binding to human rHer2 protein. (C)
Tfab binding to both Her2+ (BT474, red; SKBR3, blue) and Her2- (MCF7, dark green; SKOV3,
grey; A2780, light green) tumor cells. (D) Competition ELISA shows that Tfab competes with
commercial Tmab for binding to Her2+ tumor cells (BT474, red; SKBR3, blue). (E) Represen-
tative ELISA binding profile of Tfab with rHer 2 (red) and rHer3 (Blue) proteins. Error bars
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represent standard deviation from technical triplicates.
(TIF)
S3 Fig. Biolayer interferometry data. Sensorgrams of soluble rHer2 (A-B) and rHer2 and
rHer3 (C-D) binding to immobilized Tfab and Tmab (Herceptin) on Fortebio biosensor tips
(Streptavidin and recombinant proteinA capture, respectively). Blue curve indicates measured
binding kinetics and red line indicates best fit curve from kinetic modeling.
(TIF)
S4 Fig. Quantified Her2 expression levels from various cancer cell lines. (A) Microsphere
beads with different level of FITC fluorescent intensity used to establish calibration curve for
flow cytometry. Flow cytometry histograms of (B) MCF7, (C) BT-474, (D) SKBR3, (E) A2780
and (F) SKOV3 cells after incubation with FITC-maleimide labeled Tfab. Molecules of equiva-
lent soluble fluorochrome (estimated receptor number per cell) were interpolated from the
microbead calibration curve.
(TIF)
S5 Fig. In vitro cellular specificity of IONP constructs. Representative 100 nm IONP-Tfab
and 100 nm IONP-Mal binding to Her2 negative (MCF7) and positive (BT-474) tumor cells.
Mean values with standard deviation.
(TIF)
S6 Fig. In vitro rHer2 binding affinity of PEGylated IONP constructs. (A) 30 nm IONP-
Tfab-PEG (closed circles) and 30 nm maleimide IONP-PEG (open squares). (B) 100 nm
IONP-Tfab-PEG (closed circles) and 100 nm maleimide IONP-PEG (open squares).
(TIF)
S7 Fig. Tissue iron concentration normalized to blood iron concentration for each treat-
ment group. Iron content of various tissue compartments was quantified 24 hours post injec-
tion by ICP-MS, and the averaged values from Fig. 4 were normalized to blood iron content
from Fig. 4. This normalization corrects for tissue iron content contributed by residual blood
within the given tissue compartment. (A) Tumor, (B) Liver, (C) spleen, (D) Kidney, (E) Lung,
(F) Heart. Statistical significance (P<0.05;  P<0.01; P<0.0001) was analyzed by one
way ANOVA with a Dunnett multiple comparison posttest to PBS.
(TIF)
S8 Fig. Photomicrographs representing immunohistochemistry on tumors excised from
murine models. (A) Tissue sections of HER2 positive human BT474 breast cancer tumors,
and (B) MTGB HER2 negative murine adenocarcinoma tumors. HER2 staining in BT474 cells
is significantly associated with the cell membrane (brown) but can also clearly be seen in the
cytoplasm of many cells. The HER2 negative MTGB cells do not demonstrate any appreciable
HER2 staining.
(TIF)
S1 File. Supplemental material and methods information.
(DOC)
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